Since MTAP deletion happens frequently in osteosarcoma and its synthetic lethality pair PRMT5 inhibitor might target normal cells in vivo, our microrobots might become a new delivery approach to deliver the synthetic lethal drug directly to the tumor site to enhance the drug efficiency and reduce the side effects. The gene discussed is PRMT5; the disease is osteosarcoma.